BioCatalystWatch
DRUGWorkspace / DRUG / OverviewCompany library
BRIGHT MINDS BIOSCIENCES INC. logo

BRIGHT MINDS BIOSCIENCES INC.

BRIGHT MINDS BIOSCIENCES INC. (DRUG)

Website

Price
Market cap
Next catalystAdditional data including long-term outcomes throughout 2026BMB-101 — BREAKTHROUGH absence-seizure cohort · Phase 2 dataCompany release ↗
Cash

Chart & Events

Candle interval

Core Clinical

BMB-101

5-HT2C

PreINDP1P2P3FilingApproved
Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

BMB-101

5-HT2C

PreINDP1P2P3FilingApproved
Upcoming / outlook

Other pipelines

BMB-101

5-HT2C

PreINDP1P2P3FilingApproved
JJ42

5-HT2C

PreINDP1P2P3FilingApproved
BMB-202

5-HT2A

BMB-105

5-HT2C

PreINDP1P2P3FilingApproved
BMB-105

5-HT2C

PreINDP1P2P3FilingApproved
BMB-201

5-HT2A × 5-HT2C × 5-HT1F × 5-HT6

Financial position

Short-term investments

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

DRUG PR & News

PR & News

DRUG SEC archive